H. Pylori and Peptic Ulcers in Patients with Liver Cirrhosis


Researchers investigating the development of peptic ulcers in patients with liver cirrhosis reported that H. pylori is not the predominant etiology in this population.

To determine whether Helicobacter pylori (H. pylori) plays a central role in the development of ulcers in patients with liver cirrhosis and peptic ulcers, the authors of “Helicobacter Pylori Is not the Predominant Etiology for Liver Cirrhosis Patients with Peptic Ulcer Disease,” published in the European Journal of Gastroenterology and Hepatology,” identified a cohort of patients with a diagnosis of liver cirrhosis in an inpatient setting based on the presence of International Classifications of Diseases, Revision 9, and Clinical Modification (ICD-9-CM) codes 571.2, 571.5, and 571.6 in their records. Patients whose records did not include those ICD-9-CM codes were designated as not having liver cirrhosis (non-LC).

For the study, investigators identified 9,465 H. pylori-positive patients and 3,418 H. pylori-negative patients and analyzed their records to determine whether liver cirrhosis was an independent factor of lower H. pylori infection rates in patients with peptic ulcer.

The authors identified 102 patients with decompensated liver cirrhosis who also had peptic ulcers (39 were H. pylori-positive, 63were H. pylori-negative). They identified 360 patient with compensated liver cirrhosis who had peptic ulcers (193 H. pylori-positive, 167 H. pylori-negative).

Among patients with no liver cirrhosis who had peptic ulcers, 9,233 were H. pylori-positive and 3,188 were H. pylori-negative.

Analysis of the data revealed that patients with decompensated liver cirrhosis (OR=0.23, P<0.001) and patients with compensated liver cirrhosis (OR=0.48, P<0.001) had lower H. pylori infection rates.

Based on these results, the authors concluded that H. pylori is not the predominant etiology for liver cirrhosis, “especially the decompensated type, either with peptic ulcer disease or with recurrent ulcer disease.”

Related Videos
Better Fecal Live Microbiota Outcomes Linked to Gut Microbiome Health
Paul Feuerstadt, MD: Preventing Recurring C Difficile Infection in Older Adults with Comorbidities
Uma Mahadevan, MD: Prioritizing Gastric Health in Gestational Care
Brian Lacy, MD, PhD: Tailoring Treatment Experiences for IBS-C Patients
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Tenapanor Provides Varied Timing for IBS-C Symptom Relief
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Rene Gomez-Esquivel, MD: Screening for Pediatric Colon Cancer
Rene Esquivel Gomez, MD: Pediatric Endoscopy and Colonoscopy Strategies
Tegan Medico, MS, MPH, RDN, CNSC: Diet and Nutrition Management in Pediatric Gastric Disease
© 2023 MJH Life Sciences

All rights reserved.